Note: Please read our disclaimer at the bottom of the article.
#StrongHands 🙌 #BOP 🚀 Nation Update ️️️️️️️️️️️️️️️️️️️❤️️
Hi, I’m Paul Mampilly.
Welcome to my company's Substack, where we provide daily coverage of #OGI (opportunity, growth, and innovation) market trends, macro level analysis, and stock picks.
Like our name suggests, at ATG Digital, we go Against the Grain to support everyday people on their investing journeys.
ATG also represents seeing the world for what is abundantly clear to see — an opportunity for incredible growth and the BRIGHT and PROSPEROUS future that lies ahead.
To aid you on your journey to financial freedom, we have five paid plans starting at $9.99 for you to consider.
With a subscription you get:
Premium Content: Weekly market and stock updates via email newsletter.
Stock Picking Guidance: Flash (buy/sell) alerts with targeted price points.
Model Portfolio Access: Access to LIVE portfolios.
Webinars: Private events with the team based on ideas preselected by you.
(Purple Tier Members)
Just visit atgdigital.media to see which plan is the best fit for your journey!
Substack 🥞 subscribers: 5,768 (+1)
Weekly 🗓 Round Up
Here’s a roundup of all our Substack articles from the week!
If you haven’t had a chance, be sure to check them out here:
Tuesday — All Eyes 👀 on THIS Cloud-Based Innovator
Wednesday — Up 900% on This Stock! 🤯
Thursday — Buy Now Pay Later for Tacos? 🤔
Dan: Can’t Get Enough 🤩
Many of our latest buy recommendations were in the biotech/biopharma sector.
The technology and innovation developing in this sector is groundbreaking.
Today, I’ll cover one leader in this incredible industry . . .
This Company Exploded 💥 Onto the Scene
We’ve held Moderna Inc. (Nasdaq: MRNA) in our Silver Tier model portfolio since 2021.
At one point, we were sitting on over a 100% gain. Over the last few years, however, the stock price fell during the market crash.
MRNA 0.00%↑ exploded when its COVID-19 vaccine was validated. In 2021 and 2022, it brought in $17.7 billion and $18.9 billion in revenue, respectively.
Since the end of the pandemic mania, MRNA 0.00%↑ saw revenue of $6.8 million in 2023. This decrease in revenue led to its stock dropping.
But now, there’s very promising developments in MRNA 0.00%↑’s pipeline . . .
A Word From the CEO 🗣️
MRNA 0.00%↑ expects regulatory approvals for its investigational RSV vaccine for older adults beginning in the first half of 2024 and anticipates additional key milestones from its late-stage pipeline this year.
In MRNA 0.00%↑’s latest quarterly update, CEO Stephane Bancel stated:
2023 was a year of transition for Moderna as we adapted to the endemic market. At the same time, our development team made significant pipeline advancements across infectious diseases, oncology, and rare diseases, while our commercial team increased our COVID-19 market share in the U.S. We look forward to the anticipated approvals of our RSV vaccine beginning in the first half of the year. With multiple upcoming Phase 3 data readouts in 2024, we remain focused on commercial execution and continued investment in our pipeline with financial discipline.
As you can see, MRNA 0.00%↑ has much to look forward to!
Launching 🚀 a New Vaccine
One vaccine in the company’s pipeline is its RSV vaccine (mRNA-1345), which is expected to achieve regulatory approval in the first half of this year.
Should it be approved, MRNA 0.00%↑ would benefit from indications of widespread consumer awareness and established demand in the RSV market.
Awareness of this vaccine and demand for it will make it a candidate for adoption.
That’s mostly due to its robust efficacy data, its safety and tolerability profile, as well as serving as the only pre-filled syringe (PFS) product available at the time of launch.
The PFS ready-to-use formulation will save pharmacists and clinicians time and potentially help reduce administration errors: a win-win for consumers and health care professionals.
Currently, MRNA 0.00%↑ has a $40 billion market cap with $13.3 billion in cash. This should be enough to fuel operations and growth.
More Where This Came From 👀
With its promising pipeline and an attractive timeline, we remain bullish on MRNA 0.00%↑. We’ll continue to hold it in our Silver Tier model portfolio.
For more opportunities in the biotech sector and beyond, consider subscribing to our services for as little as $9.99 by clicking here!
Just look at biotech gains we closed in 2023:
Don’t miss out — join the ATG Digital family today! 🤗
#GBC100: Friday, March 15, 2024
The #GBC100 is up 0.03% today.
With markets shifting in our direction, there isn’t anything new to write about. So, just to let you know, we won’t always be commenting on the performance of the #GBC100 daily.
However, we’ll be updating the performance, and we want to remind folks that our goal is to turn the #GBC100 into an ETF that offers a one-stock way to invest the ATG way — in innovation and growth.
To learn more or express your support for the launch of an ETF (by completing a poll), click here.
Next Week: Paul will discuss a company that’s always making headlines! 👀
Today, Dean released a new YouTube video. 📺
In it, he discusses a Bitcoin USD (BTC-USD) hoarding machine.
Be sure to watch it here! 👇
Please let us know what you think in the comment section!
On Friday, March 15, 2024, we hope to hear from you. 😉
❤️️ This Substack made — by US, for YOU — with love. ❤️️
Questions? Concerns? 🤔 Look Below 👇
Have questions or trouble accessing your account? Please reach out to us at info@atgdigital.media or schedule a call, and our Customer Support team will be happy to help.
You can also check our FAQ page on our website for an up-to-date list of questions and answers. Your question may have been addressed there.
*Please be advised that customer support calls are limited to 15 minutes and will strictly cover your membership subscription and billing needs only. Any calls that are disrespectful in nature may be subject to immediate termination.
Join us, be #BOP 🚀, be #StrongHands 🙌, #GoATG! ️️❤️️
Disclaimer/Legal Stuff Written in Plain English
What you read/watch/hear is OPINION, not financial/investment advice. Treat it no different than when you read/watch/hear your favorite author/YouTuber/podcaster. Despite our best efforts, we get things wrong and make mistakes. Investing is risky. There is no guarantee you will make money. Your investments may lose value. That’s RISK. Past performance is no guarantee of future results. Employees, contractors, and owners of ATG Digital, LLC own/trade/transact in the stocks, options, and crypto that are the subject of our trade alerts, updates, reports, and commentaries. We cannot give you personalized financial advice because we are NOT financial advisors. It’s on you to decide how much/when/what to buy/sell based on YOUR financial needs, plans, and risk preferences. There are no guarantees. Loss of your capital is an outcome that you should evaluate carefully with a financial advisor before you trade, speculate, or invest. It's your money and your responsibility.